Observational studyThe Journal of clinical endocrinology and metabolism2022
Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
Observational study in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.Frontiers in endocrinology · 2023Trial
- Sleep patterns and glycemia in adults with cystic fibrosis-related diabetes: a remote pilot study.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Article
- The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review.Diabetologia · 2026Article
- The endocrine complications of cystic fibrosis.Nature reviews. Endocrinology · 2026Review
- Relationship Between Laboratory-Measured HbA1c and Continuous Glucose Monitoring-Derived Glucose Management Indicator in Adults With Cystic Fibrosis-Related Diabetes.Diabetes care · 2026Article
- Continuous glucose monitoring (CGM) systems in Poland, Europe, and beyond in 2025: principles, available technologies, and future perspectives.Archives of medical science : AMS · 2026Article
- A Linear and High-Sensitivity Microwave Biosensor on a FR-4 Substrate for Aqueous Glucose Monitoring Using a Concentric Square-Shaped Split-Ring Resonator.Sensors (Basel, Switzerland) · 2025Article
- Alternative approaches to glucose measurements during oral glucose tolerance testing in youth with cystic fibrosis: a mixed methods pilot study.Journal of clinical & translational endocrinology · 2025Article
- Time to replace the oral glucose tolerance test for cystic fibrosis related diabetes first-step screening? Establishing glycemic tools relevant to cystic fibrosis.Annals of medicine · 2025Article
- Continuous Glucose Monitoring in People at High Risk of Diabetes and Dysglycaemia: Transforming Early Risk Detection and Personalised Care.Life (Basel, Switzerland) · 2025Review
- Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO.The Journal of clinical endocrinology and metabolism · 2025Observational
- Utility of Continuous Glucose Monitors for Improved Detection of Cystic Fibrosis-Related Diabetes.Pediatric pulmonology · 2025Article
- Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance.American journal of physiology. Endocrinology and metabolism · 2025Article
- Accuracy of continuous glucose monitoring in the hospital setting: an observational study.Diabetologia · 2024Observational
- Advances in diabetes technology to improve the lives of people with cystic fibrosis.Diabetologia · 2024Review
- The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.Medicina (Kaunas, Lithuania) · 2024Review
- Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.Frontiers in endocrinology · 2024Observational
- Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study.Frontiers in nutrition · 2024Article
- Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study.Frontiers in endocrinology · 2024Article
- Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?Journal of diabetes science and technology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
contextThe clinical utility and implications of continuous glucose monitoring (CGM) in cystic fibrosis (CF) are unclear.
objectiveWe examined the correlation between CGM measures and clinical outcomes in adults with CF, investigated the relationship between hemoglobin A1c (HbA1c) and CGM-derived average glucose (AG), and explored CGM measures that distinguish cystic fibrosis-related diabetes (CFRD) from normal and abnormal glucose tolerance.
methodsThis prospective observational study included 77 adults with CF who had CGM and HbA1c measured at 2 to 3 time points 3 months apart.
resultsThirty-one of the 77 participants met American Diabetes Association-recommended diagnostic criteria for CFRD by oral glucose tolerance testing and/or HbA1c. In all participants, CGM measures of hyperglycemia and glycemic variability correlated with nutritional status and pulmonary function. HbA1c was correlated with AG (R2 = 0.71, P < 0.001), with no significant difference between this regression line and that previously established in type 1 and type 2 diabetes and healthy volunteers. Cutoffs of 17.5% time > 140 mg/dL and 3.4% time > 180 mg/dL had sensitivities of 87% and 90%, respectively, and specificities of 95%, for identifying CFRD. Area under the curve and percent of participants correctly classified with CFRD were higher for AG, SD, % time > 140, > 180, and > 250 mg/dL than for HbA1c.
conclusionCGM measures of hyperglycemia and glycemic variability are superior to HbA1c in distinguishing those with and without CFRD. CGM-derived AG is strongly correlated with HbA1c in adults with CF, with a similar relationship to other diabetes populations. Future studies are needed to investigate CGM as a diagnostic and screening tool for CFRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.